Jane Street’s C4 Therapeutics CCCC Stock Holding History

Jane Street’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$235K	Sell	50,300 -36,500	-42%	-$125K	﹤0.01%	9744
2026 Q1	$228K	Buy	+86,800	New	+$204K	﹤0.01%	9841
2024 Q4	–	Sell	-32,800	Closed	-$187K	–	9472
2024 Q3	$187K	Sell	32,800 -34,800	-51%	-$209K	﹤0.01%	8692
2024 Q2	$312K	Buy	67,600 +9,000	+15%	+$53.7K	﹤0.01%	7738
2024 Q1	$479K	Sell	58,600 -107,200	-65%	-$831K	﹤0.01%	6753
2023 Q4	$937K	Buy	+165,800	New	+$378K	﹤0.01%	5677
2022 Q3	–	Sell	-34,000	Closed	-$256K	–	9745
2022 Q2	$256K	Buy	34,000 +1,100	+3%	+$9.68K	﹤0.01%	7840
2022 Q1	$798K	Buy	32,900 +16,000	+95%	+$389K	﹤0.01%	6589
2021 Q4	$544K	Buy	+16,900	New	+$668K	﹤0.01%	7098

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street's CCCC Position: Q2 2026 in Review

Jane Street reduced its C4 Therapeutics (CCCC) stake by 76% in Q2 2026, selling an estimated $3.23M and leaving 302,750 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #5799.

Jane Street first reported a position in CCCC in Q1 2021 and has held it in 15 quarters since. The position peaked at $3.28M in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Jane Street held 302,750 shares of C4 Therapeutics worth $1.41M as of Q2 2026.
Jane Street sold 944,146 C4 Therapeutics shares in Q2 2026, an estimated $3.23M.
C4 Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5799 holding.
Jane Street first reported a position in C4 Therapeutics in Q1 2021 and has held it in 15 quarters since.
Jane Street's C4 Therapeutics position peaked at $3.28M in Q1 2026.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.